NanoRepro AGXTER:NN6 63 Net Margin % is -32.83% as of Jun. 2025. GuruFocus rates XTER:NN6 with a GF Score™ of 63/100 and a GF Value™ of €1.01 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, NanoRepro AG ranks worse than 69.46% on this metric.
Net margin is calculated as Net Income divided by its Revenue. NanoRepro AG's Net Income for the
six
months ended in Jun. 2025 was €-0.84 Mil. NanoRepro AG's Revenue for the
six
months ended in Jun. 2025 was €2.57 Mil. Therefore, NanoRepro AG's net margin for the quarter that ended in Jun. 2025 was -32.83%.
The historical rank and industry rank for NanoRepro AG's Net Margin % or its related term are showing as below:
XTER:NN6'
s Net Margin % Range Over the Past 10 Years
Min: -220.64 Med: -39.65 Max: 18.26
Current: -32.19
XTER:NN6's Net Margin % is ranked worse than 69.46% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.43
vs XTER:NN6: -32.19
NanoRepro AG (XTER:NN6) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
NanoRepro AG Net Margin % Related Terms
NanoRepro AG Net Margin % Historical Data
* Premium members only.
The historical data trend for NanoRepro AG's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:NN6 vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, NanoRepro AG's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NanoRepro AG Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NanoRepro AG's Net Margin % distribution charts can be found below:
* The bar in red indicates where NanoRepro AG's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NanoRepro AG (XTER:NN6) has a Net Margin % of -32.83% as of Jun. 2025. Net margin is the ratio of total net income to net sales. View historical data on NanoRepro AG and its competitors. According to the industry distribution chart, NanoRepro AG ranks #141 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 69.5%.
Is NanoRepro AG's Net Margin % too high?
NanoRepro AG's current Net Margin % is -32.83%. Based on the distribution chart, NanoRepro AG ranks #141 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, NanoRepro AG has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NanoRepro AG's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, NanoRepro AG ranks #141 out of 203 companies for Net Margin %. This places NanoRepro AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on NanoRepro AG and its competitors. NanoRepro AG's current Net Margin % is -32.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NanoRepro AG stock overvalued right now?
Based on GuruFocus' analysis, NanoRepro AG (XTER:NN6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.01, compared to a current price of €2.08 — trading 105.9% above its estimated fair value. The current Net Margin % is -32.83%. NanoRepro AG's overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For NanoRepro AG (XTER:NN6), the current Net Margin % is -32.83% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NanoRepro AG (XTER:NN6) Overvalued in 2026?
Based on GuruFocus' analysis, NanoRepro AG stock appears to be overvalued.
The current stock price of €2.08 is trading 105.9% above its estimated GF Value™ of €1.01.
GuruFocus considers NanoRepro AG to be Significantly Overvalued.
Key valuation signals for XTER:NN6:
Net Margin %: -32.83%
GF Value™: €1.01 vs. price of €2.08 (105.9% above fair value)
No single metric tells the full story. See the XTER:NN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use.
63GF Score
Get the complete analysis for XTER:NN6
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:NN6 has been successfully added to your 
